A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

A total of approximately 300 adult participants that has received at least one study drug treatment and completed one follow-up visit in the parent studies will be enrolled. Each participant will undergo three follow-up visits, scheduled every three months in Stage 1.

Inclusion criteria

• Participant must have received at least 1 treatment of CBL 514 or Placebo and completed the FU1 visit of the parent study.
• Participant is willing to maintain a stable lifestyle.
• Participant voluntarily signs the Informed Consent Form (ICF) for Stage 1 and, in the opinion of the Investigator or delegate, is physically and mentally capable of participating in the study, and willing to adhere to the study procedures.

Exclusion criteria

• Participant has had or will be undergoing treatment that may affect the evaluation of the treated area.
• Participant is taking prescription or over the counter (OTC) weight reduction medication or is in a weight reduction program.
• Participant has an unstable condition or is otherwise thought to be unreliable or incapable of complying with the requirements of the protocol.
• Female participant of childbearing potential who is not willing to commit to an acceptable contraceptive method or who is currently pregnant or lactating. Male participant who is not committed to using condoms consistently throughout the study. Ova and sperm donation are to occur after a certain washout period post IP treatment.